Lytix Biopharma AS
Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic… Read more
Lytix Biopharma AS (LYTIX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.969x
Based on the latest financial reports, Lytix Biopharma AS (LYTIX) has a cash flow conversion efficiency ratio of -0.969x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-59.85 Million) by net assets (Nkr61.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lytix Biopharma AS - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Lytix Biopharma AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Lytix Biopharma AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lytix Biopharma AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bitech Technologies Corporation
OTCQB:BTTC
|
-0.031x |
|
Samyang Packaging
KO:272550
|
0.073x |
|
Daejung Chemicals & Metals Co.Ltd
KQ:120240
|
0.023x |
|
Kabra Extrusion Technik Limited
NSE:KABRAEXTRU
|
-0.022x |
|
Launch Technologies Co Ltd
TWO:8420
|
-0.036x |
|
reAlpha Tech Corp. Common Stock
NASDAQ:AIRE
|
-0.389x |
|
FGV Holdings Bhd
KLSE:5222
|
0.039x |
|
Vertoz Advertising Limited
NSE:VERTOZ
|
0.019x |
Annual Cash Flow Conversion Efficiency for Lytix Biopharma AS (2017–2025)
The table below shows the annual cash flow conversion efficiency of Lytix Biopharma AS from 2017 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr61.75 Million | Nkr-59.85 Million | -0.969x | -48.60% |
| 2024-12-31 | Nkr107.89 Million | Nkr-70.37 Million | -0.652x | +65.12% |
| 2023-12-31 | Nkr51.32 Million | Nkr-95.97 Million | -1.870x | -385.00% |
| 2022-12-31 | Nkr135.13 Million | Nkr-52.10 Million | -0.386x | -62.86% |
| 2021-12-31 | Nkr189.62 Million | Nkr-44.90 Million | -0.237x | +80.66% |
| 2020-12-31 | Nkr19.89 Million | Nkr-24.35 Million | -1.224x | +54.85% |
| 2019-12-31 | Nkr13.58 Million | Nkr-36.82 Million | -2.711x | -53.27% |
| 2018-12-31 | Nkr41.05 Million | Nkr-72.62 Million | -1.769x | +70.06% |
| 2017-12-31 | Nkr11.79 Million | Nkr-69.67 Million | -5.909x | -- |